sales@jinjingroup.com

  News Introduction

3,4-Dihydroxybenzaldehyde(cas 139-85-5) and pharmaceutical intermediates

Date : 2016/8/23 11:59:13

3,4-Dihydroxybenzaldehyde(cas 139-85-5) is used as pharmaceutical intermediates. In fact, pharmaceutical intermediates are the raw materials or chemical products for pharmaceutical synthesis process for some chemical. Some medicines for the synthesis of pharmaceutical intermediates, the term should be considered as general designation of some chemical products. Pharmaceutical intermediates is an important part of fine chemicals, the level of pharmaceutical intermediates development is a country's level of modernization of chemical markers. Over the years, the pharmaceutical industry is the focus of the world intermediates focus on investment and competitive.

The past two decades, the pharmaceutical industry around the world has made unprecedented progress, to the late 1990s, the world pharmaceutical market reached $ 256 billion / a about pesticide sales $ 23 billion / a or so. On medicine is concerned, over the past decade although biotechnology and genetic medicine as a rookie in constant development, has also been an important medicine for people to accept.

The future development trend of the world pharmaceutical industry are: high-tech, high demand, high-speed, high concentration.

Main features:

1. Drug endless varieties. Nearly 30 years ago, has more than 20,000 chemical synthesis and antibacterial compounds screened. 3,4-Dihydroxybenzaldehyde(cas 139-85-5) is one of them.
2. Drug Discovery is getting more and more difficulty, administration of drug efficacy and safety requirements is more higher, so investment in research and development surge. At the same time, drug research and development is a long-term continuity; and there is a great risk. To accommodate the high-tech field of competition, we need to spend huge amounts of money.
3. The pharmaceutical industry as a high-tech industry, a high knowledge content is required. States pharmaceutical industry are constantly strengthening its research team strength. Such as the US pharmaceutical companies employing researchers accounted for 15%, including doctorate, master's degree accounted for 26.7% of researchers.